Solvay announced that it will invest in Suanfarma’s Cipan manufacturing site located in Lisbon, Portugal to develop its capabilities for natural ingredients. The transaction, which will be completed by mid-2023, is the first step of a long-term partnership with Suanfarma, which is held by ArchiMed, a global life science investment firm.
 
This will enable Solvay to deepen its capabilities for natural ingredients in food, flavors, and fragrances industries, the company said.
 
“Solvay is already a leader in natural ingredients. Now, with this exciting investment we will pave the way for further growth in naturals. The investment is in line with our newly formed renewable materials and biotechnology growth platform, and will boost our ability to meet our customers’ long-term needs and enable the switch to bio-sourced and natural ingredients,” said An Nuyttens, aroma and silica global business units president, Solvay.
 
“This first step of our collaboration with Suanfarma provides access to efficiently raise our existing capacities on natural ingredients, including through our flagship natural vanillin, Rhovanil Natural CW. Produced through a natural fermentation process with the highest standards of quality control and traceability, Rhonavil Natural is manufactured in Europe and offers reliable and future-proof supply to our customers,” said Jo Grosemans, Solvay’s natural growth director.
 
Solvay’s production process is in line with its growth platform, “Renewable materials and biotechnology,” which aims to meet global demand for sustainable solutions through biotechnology.